News

Luminoah, Rivanna Medical selected to prestigious med-tech accelerator

Two Charlottesville startups have been selected to MedTech Innovator, a well-known accelerator for medical technology startups.

Luminoah and Rivanna Medical are among 65 companies selected for the Los Angeles-based accelerator’s 2025 cohort. They will participate in a four-month program geared toward accelerating a path to U.S. market success.

Luminoah and Rivanna were both selected in the diagnostic and monitoring category. Luminoah, a former Lighthouse Labs demo day winner that closed a $6 million Series A round in 2023, has developed a mobile feeding tube for patients that collects data. Rivanna offers four products using ultrasound-based imaging technology that it says offer better precision and efficiency to health care professionals.

The MedTech Innovator program will include access to MedTech Innovator’s ecosystem of manufacturers, investors, providers, patients and more. The accelerator’s alumni have collectively brought more than 400 products to market and raised roughly $10 billion in follow-on funding, according to MedTech Innovator.

The 65 selected companies will compete for a share of $800,000 in nondilutive funding. The winners will be selected by audience vote at industry conferences.

MedTech Innovator said it received nearly 1,500 applicants to the program. It ultimately invited 213 companies to pitch at road tour events in Los Angeles, Dublin and College Park, Maryland, and then whittled that field down to 65.

The cohort represents 13 countries and 17 U.S. states.

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation